No profile data available.
Corvus Pharmaceuticals, Inc. (CRVS) is a healthcare company in the blood cancer treatment drugs industry, based in South San Francisco, United States, with about 37 full-time employees.
It reported revenue of $0 for fiscal year 2025, and net income of -$15.28 million. Its market capitalization was $884.95 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
, a clinical stage biopharmaceutical company, engages in the development of product candidates that precisely target proteins that are critical to immune cell maturation and function in the United States.
Corvus Pharmaceuticals reported $0 in revenue for fiscal year 2025.
$884.95 million as of October 9, 2026.
Listed companies of a similar size in the same industry (blood cancer treatment drugs) include Ascentage Pharma Group International (AAPG), Vor Biopharma Inc. (VOR), Kura Oncology, Inc. (KURA), OmniAb, Inc. (OABI).